Review of the Characteristics of Itraconazole and Terbinafine as Conventional Antifungal Agents

DOI Web Site

Bibliographic Information

Other Title
  • 爪白癬これまでの内服療法－イトラコナゾールとテルビナフィン－
  • ツメ ハクセン コレマデ ノ ナイフク リョウホウ : イトラコナゾール ト テルビナフィン

Search this article

Abstract

Dermatophytosis represents a large percentage of superficial dermatomycosis. The most prevalent type is tinea, with about 20% of Japan's population speculated to have tinea pedis, and about 10% to have tinea unguium. Tinea unguium is notorious for its intractability, and effective cure has remained elusive. Systemic antifungal treatment had been mainly used until the more recent introduction of two insurance-covered topical antifungal agents. Griseofulvin came out in 1962, followed by itraconazole and terbinafine in the 1990's. These three drugs had taken a central role in the treatment of tinea unguium for a long time. After griseofulvin went out of production due to shortage of material in 2008, itraconazole and terbinafine became the pillars of treatment. Last year, a new systemic antifungal agent, fosravuconazole, was released for the first time in 21 years. With the appearance of this new agent, we review the characteristics of itraconazole and terbinafine.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top